Detailseite
Projekt Druckansicht

Die Rolle des Tumorsuppressorgens NDRG2 in Angiogenese und Wundheilung

Antragsteller Dr. Dominic Henn
Fachliche Zuordnung Orthopädie, Unfallchirurgie, rekonstruktive Chirurgie
Förderung Förderung von 2018 bis 2021
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 415620923
 
Erstellungsjahr 2022

Zusammenfassung der Projektergebnisse

We have demonstrated that downregulation and knockout of NDRG2 in DCs significantly increases the secretion of VEGF from DCs, thus enabling these cells to promote angiogenesis and tissue regeneration. Based on these findings, we have developed a novel cell-based therapy for wound healing by seeding genetically engineered DCs on pullulan-collagen hydrogels and thereby were able to accomplish significantly faster healing rates compared to wildtype cells. Since clinical-grade manufacturing of autologous DCs for adoptive cell transfer is already well established in clinical practice and DC immunotherapy is already being used in multiple clinical trials, we believe that genetically edited DCs have a high potential for successful clinical translation as a cell-based therapy for patients suffering from complex wounds that are refractive to treatment with the current standard of care. In future clinical applications, DC harvest could easily be performed from standard blood samples obtained at wound clinics, without the need for tissue biopsies or other surgical interventions. In summary, our genetically edited DC therapy provides a highly effective, robust, and ready-to-use approach for the treatment of chronic wounds. It provides strong evidence towards and opens the door for future clinical trials of DC therapy combined with gene editing. These findings may provide significant translational opportunities to help patients with diabetic and non-diabetic ulcers.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung